

Nivolumab CheckMate025

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE




### ADJUSTMENTS

#### Quality of life



Improved QoL

#### Serious and disabling adverse effects



Less serious and disabling adverse events observed

#### Other adjustments



Nivolumab CheckMate025

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Genitourinary Cancers  
Therapeutic Indication: As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults  
Experimental Arm: Nivolumab  
Control Arm: Everolimus



